BPC-157 Pharmacokinetics: Exploring Its Absorption, Distribution, Metabolism, and Excretion

BPC-157 Pharmacokinetic Research

Pharmacokinetic research examines how a compound behaves in the body over time. For BPC-157, the available experimental work includes studies of plasma exposure and ADME characteristics. The main integrated study examined BPC-157 pharmacokinetics, distribution, metabolism, and excretion in rats and beagle dogs. It used quantitative plasma measurements and radiolabeled BPC-157 to characterize the peptide experimentally.

The evidence base is primarily preclinical. The rat and beagle dog study provides the main integrated ADME dataset, while a separate in-vitro study examined BPC-157 metabolism in plasma.

BPC-157 Plasma Concentration and Half-Life

BPC-157 plasma concentrations were measured over time in rats and beagle dogs. The researchers generated concentration-time profiles after intravenous administration and after intramuscular administration at several experimental levels. Maximum plasma concentration was also measured. In both species, Cmax and AUC increased with the tested intramuscular levels.

The reported plasma elimination half-life was short. Following intravenous administration, it was approximately 15.2 minutes in rats and 5.27 minutes in beagle dogs. The study therefore measured rapid elimination of BPC-157 from the circulating plasma compartment.

BPC-157 Bioavailability Across Experimental Species

The primary pharmacokinetic study found a clear difference between the two experimental species. In Sprague Dawley rats absolute bioavailability was 18.82%, 14.49% and 19.35% across the three tested levels. In beagle dogs, the corresponding values were 45.27%, 47.64%, and 50.56%.

The measured systemic bioavailability was therefore higher in beagle dogs than in rats across the tested levels. The study supports a species related difference in BPC-157 bioavailability, with the dog values consistently above those measured in rats.

BPC-157 Tissue Distribution

Tissue distribution was examined in rats with tritium-labeled BPC-157. Radioactivity was measured in sampled organs and tissues after administration. The researchers examined the brain, heart, kidneys, liver, spleen, lungs, stomach, intestine, muscle, adipose tissue, reproductive tissues, and thymus.

Labeled material was detected across the sampled tissues. The kidney showed relatively high measured levels. Material was also detected in the liver, stomach, spleen, thymus, intestine, lungs, muscle, and other sampled sites. Brain and adipose tissue showed lower measured levels than several of the other tissues examined.

BPC-157 Metabolic Transformation

The 2022 rat ADME study detected the BPC-157 parent peptide and six additional radioactive components, designated M1 through M6. M1 was identified as proline. M2 through M6 were characterized as small molecular peptide fragments associated with BPC-157 degradation although their structures were proposed rather than definitively established.

The study described a progressive breakdown of BPC-157 from the parent peptide into smaller molecular fragments and, ultimately, single amino acids. A separate in-vitro plasma study also reported formation of a stable BPC-157 metabolite during incubation.

BPC-157 Excretion Pathways

The excretion study used tritium labeled BPC-157 and measured recovered radioactivity in experimental samples. Urine and bile were identified as the principal excretory pathways in the rat experiments.

Fecal elimination was also measured in intact rats during the 72-hour collection period. The study therefore provided direct measurements of urinary, biliary, and fecal recovery of BPC-157-related material.

BPC-157 Formulation and Molecular Stability

Experimental studies have used BPC-157 in neutral cream formulations. One study prepared the peptide by dissolving BPC-157 in saline and incorporating it into neutral cream. The authors reported

favourable peptide stability in the tested preparation.

Another experimental study also prepared BPC-157 cream by mixing the peptide solution with a commercial neutral cream.

The experimental literature therefore documents BPC-157 in neutral cream preparations and reports stability in the tested preparation. It does not provide a controlled comparison of BPC-157 integrity across different formulations or a systematic formulation-stability profile.

BPC-157 Pharmacokinetic Gaps and Future Research

Human pharmacokinetic characterization remains limited. The available human study involved only two participants and did not provide a complete human plasma concentration-time profile or a full set of human PK parameters.

The existing research also does not establish how the experimental animal findings translate to humans. A defined BPC-157 exposure-response relationship has not been established in the available studies.

Further controlled ADME research is needed to characterize BPC-157 pharmacokinetics in humans and to define exposure-response relationships. Additional analytical work is also needed to characterize BPC-157 metabolites more fully.

Research-only CTA: Explore the peptide category at Direct SARMs to review available research compounds and their scientific specifications.

FAQs

References

1. He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022 Dec 14;13:1026182. PubMed ↗
2. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017 Oct;9(10):1490-1498. PubMed ↗
3. Tian T, Jing J, Li Y, Wang Y, Deng X, Shan Y. Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS. Molecules. 2023 Oct 30;28(21):7345. PubMed ↗